Legal
Aubrey de Grey has been accused by two women of predatory behavior, an allegation de Grey denies. SENS has placed him on administrative leave pending further investigation.
Republican Senator Rand Paul is under fire from government watchdogs for failing to properly disclose a $15,000 purchase of Gilead Sciences stock made by his wife last year.
Emergent BioSolutions has approval to resume manufacturing vaccines, but its lawsuit issues haven’t gone away as easily.
The settlement is a huge development for the class action lawsuit against Takeda, which has been going on since 2016.
The Trump White House removed Bright from his position at BARDA and reassigned him to a narrower role at the National Institutes of Health.
Legal firms are lining up to lead litigation against the company on behalf of shareholders who saw their stock dive.
CytoDyn files a lawsuit against the activist group led by Rosenbaum and Patterson, alleging that they are “waging an illegal proxy contest to take over control of the Company’s Board of Directors.”
Biosimilars have gained traction in Europe, but not in the U.S. AbbVie’s Humira is often made as an example of how companies are using legal tactics to delay biosimilar competition.
The filing accused Mayne Pharma, which also has operations in the U.S., of breaching disclosure obligations with regard to anti-competitive conduct.
Rep. Michael McCaul issued a third installment today into the origins of the COVID-19 virus and blames the pandemic on a leak from the Wuhan Institute of Virology in China.
PRESS RELEASES